Union Science and Technology Minister Dr. Jitendra Singh on Wednesday, 15 July 2026 addressed the launch of Phase-III of the Biomedical Research Career Programme (BRCP), a flagship initiative jointly funded by the Department of Biotechnology (DBT) and the London-based Wellcome Trust, UK, marking a significant step in India's ambition to build a globally competitive biomedical research workforce.

Context

The Phase-III launch carries a total outlay of ₹1,500 crore, with ₹1,000 crore committed by the Department of Biotechnology and ₹500 crore contributed by Wellcome Trust UK. The funding package was cleared at a Cabinet meeting chaired by Prime Minister Shri Narendra Modi, underlining the government's institutional backing for the programme. The BRCP will continue to support fellowships and research grants aimed at nurturing biomedical researchers with international-grade credentials and visibility.

Speaking at the event, Dr. Singh stated: 'The next industrial revolution will be driven by biotechnology, and India is prepared to lead it.' He added that India's Bioeconomy is set to reach USD 300 Billion by 2030, framing the BRCP as a foundational investment in that trajectory.

Policy Backdrop

The DBT–Wellcome Trust India Alliance was formally established in 2008 as a competitive fellowship platform for early-career biomedical researchers in India, filling a structural gap in domestic research funding and international exposure. Over successive phases, the BRCP has evolved from a narrowly defined fellowship scheme into what Dr. Singh described as 'one of the most respected career platforms' in the biomedical sciences.

The programme's design — blending government budget support with foreign philanthropic capital — mirrors the approach outlined in India's National Biotechnology Development Strategy, which targeted expanded bioeconomy scale and stronger international research linkages. The DBT, established in 1986, remains the nodal body coordinating these efforts under the Ministry of Science and Technology.

Stakeholders and Impact

The primary beneficiaries are biomedical researchers, early-career scientists, and research institutions across India. Dr. Singh noted that the initiative has strengthened researchers 'not only through financial support but also by enhancing their credentials, international visibility and professional opportunities.' This positions BRCP fellows competitively in both domestic academia and global research ecosystems.

The Minister also highlighted the broader partnership model, calling the Government of India–Wellcome Trust UK collaboration 'a model of sustained international scientific collaboration and philanthropy.' He expressed hope for greater participation by philanthropic institutions and industry to translate research outputs into technologies, diagnostics, and affordable healthcare solutions — signalling an intent to expand the programme's translational scope beyond basic research.

What's Next

With Cabinet approval secured, attention now shifts to the rollout of Phase-III fellowship calls and grant cycles under the expanded ₹1,500 crore envelope. Dr. Singh's explicit call for industry and philanthropy to join the initiative suggests that new memoranda of understanding (MoUs) and co-funding arrangements could follow in the near term.

As India positions biotechnology as a pillar of its next phase of economic growth, the BRCP's Phase-III expansion represents a bet that sustained investment in research careers — backed by both state resources and international foundations — can accelerate the country's transition from a consumer to a producer of biomedical innovation.